The recent emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectious disease, COVID-19, has gripped the whole world with anxious and uncertain circumstance due to its high rate of human-to-human transmission and killer properties of infection.^[@ref1]^ COVID-19 is, primarily, caused by the interaction between SARS-CoV-2 and the host surface receptor protein, human angiotensin-converting enzyme 2 (hACE2), prior to entry into the host cell.^[@ref2]^ Therefore, hACE2 can be considered as a main check post of cellular entry of SARS-CoV-2. The SARS-CoV-2 is believed to enter through two primary entrances, nose and mouth, and then reach to mainly the lungs, brain, and intestine, where there is an abundance of hACE2. Once inside the host cell, virus impairs the host immune system, resulting in illness. The higher rate of illness and mortality risk are highly associated with older people and patients with a weakened immune system and comorbidities such as diabetes, obesity, cancer, lung disease, and hypertension.^[@ref1]^

As COVID-19 has become pandemic, scientists across the world are in a race to understand the COVID-19 enemy and discover suitable drug/vaccine to beat this infection. However, to date, no clinically approved drugs or vaccines are available in market to prevent the COVID-19 invasion. Therefore, the initial step is to search for potential candidates from existing drugs such as remdesivir, lopinavir, chloroquine, and hydroxychloroquine, etc. for the treatment of SARS-CoV-2, but their efficacy still is controversial.^[@ref3]^ Therefore, alternative antiviral agents/therapies are an urgent requirement to stop the spread of the present infection. Hence, this Viewpoint sheds light on peptide-based antiviral therapies and their feasibility, where both designed peptides (mimicking the virus binding domain of hACE2) and naturally occurring antimicrobial peptides (AMPs; first line host defense peptide^[@ref4]^) reduce cellular virus load by blocking cellular surface receptors and/or disruption of virus cell membrane at the stage of virus entry, thereby preventing COVID-19 illness.

Crystal structure reveals that specific amino acid residues at the contact interface between SARS-CoV-2 and hACE2 are essential meeting points of virus-host link-up ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref2]^ Especially, two viral hot spots, K31 and K353 on hACE2 endow a more killer nature to SARS-CoV-2 from SARS-CoV.^[@ref3]^ However, this finding gives valuable molecular insight into virus--host interaction, which may be applied to design a newer drug. Currently, several interventional tactics are being investigated in ongoing COVID-19 research. Among them, one approach seeks to modulate the virus--host interaction, which might be one of the important therapeutic interventions of COVID-19. Therefore, a designed peptide that mimics the virus binding domain of ACE2, would be a promising SARS-CoV-2 blocker. The FDA, to date, approves many peptide-like inhibitors for the treatment of several diseases including diabetes, cancer, infectious diseases, autoimmune diseases, etc., due to their easy synthesis, greater efficacy, ease of penetration into cell membrane, safety, and tolerability in humans compared to small molecules (based on the GlobalData Pharma Intelligence Center Drugs database). In fact, peptide-based inhibitors are already in line for the treatment of COVID-19. The initial step is amputation of the full length of hACE2 that specifically binds the spike protein. For instance, several fragments as antiviral peptides are extracted from hACE2 (such as, 21--43, 27--38, 22--44, 22--57, and 22--44--linker--351--357 amino acid residues ranges of ACE2) that exhibit potent antiviral activity, attributing high-binding affinity toward SARS-CoV-2.^[@ref5]^ This finding raises the interest to use a designed-peptide as an antiviral agent for the treatment of COVID-19.

![(A) Cartoon represents the attachment of SARS-CoV-2 (sky blue sphere with spike) and hACE2 (green rod). (B) Crystal structure of spike protein (sky blue) bound hACE2 (green) complex (PDB: 6m0j),^[@cit2b]^ (C) Selective amino acid residues at the contact interface between spike protein and hACE2 are highlighted with numbering (for simplicity, noncovalent interactions lines are omitted). H-bonding interaction: K417~(COVID-19)~\-\--D30~(ACE2)~, G446~(COVID-19)~\-\--Q42~(ACE2)~, Y449~(COVID-19)~\-\--D38~(ACE2)~, Y449~(COVID-19)~\-\--Q42~(ACE2)~, Y453~(COVID-19)~\-\--H34~(ACE2)~, A475~(COVID-19)~\-\--S19~(ACE2)~, F486~(COVID-19)~\-\--Y83~(ACE2)~, N487~(COVID-19)~\-\--Q24~(ACE2)~, Q493~(COVID-19)~\-\--E35~(ACE2)~, G496~(COVID-19)~\-\--D38~(ACE2)~, G496~(COVID-19)~\-\--K353~(ACE2)~, Q498~(COVID-19)~\-\--Q42~(ACE2)~, T500~(COVID-19)~\-\--Y41~(ACE2)~, N501~(COVID-19)~\-\--Y41~(ACE2)~. Electrostatic interaction: G502~(COVID-19)~\-\--K353~(ACE2)~, K417~(COVID-19)~\-\--D30~(ACE2)~, E484~(COVID-19)~\-\--K31~(ACE2)~, L455~(COVID-19)~\-\--H34~(ACE2)~. Hydrophobic interaction: F486~(COVID-19)~\-\--M82~(ACE2)~, Y489~(COVID-19)~\-\--K31~(ACE2)~, Y505~(COVID-19)~\-\-\--K353~(ACE2)~.](pt0c00081_0001){#fig1}

As is known, during infection, the innate and adaptive immune response of a host is modulated by the virus, including SARS-CoV-2.^[@ref6]^ Mounting experimental evidence supports that antimicrobial peptides (AMPs) are primary components of the innate immune system and are a first line natural barrier against infection *in vivo*.^[@ref4],[@ref7]^ AMPs are up-regulated during infection by multiple pathogens *in vivo*, through the immune pathway. On the basis of available data, the enrichment of AMPs levels, in living organisms, boosts innate and adaptive immunity that leads to antiviral activity. AMPs are, in general, small and positively charged peptides that enable electrostatic interaction with the negatively charged cell surface of multiple pathogens thereby killing many pathogens at the stage of entry level, through a common mode of action such as blocking cellular receptors and/or virus cell membrane disruption.^[@ref7]^ Currently, more than 5000 AMPs are reported, wherein ∼15% AMPs show antiviral activities against enveloped viruses.^[@ref8]^ Therefore, AMPs have gained considerable attention as therapeutic tools against infectious viral pathogens such as dengue virus (DENV), Zika virus (ZIKV), and recently SARS-CoV-2 etc.^[@ref9]^

From clinical observation of the SARS-CoV-2 infection, the digestive symptom is rare relative to respiratory- or neuro-symptom. This occurs because of high abundance of antimicrobial peptides (AMPs) in the intestine, which may play a defensive role against COVID-19 by disrupting specific virus--host interactions.^[@ref10]^ Interestingly, AMPs such as human defensin 5 (HD5) are highly expressed in the intestine and play a key role in the innate immune system in humans. A recent study highlights that HD5 shows a potent antiviral activity against SARS-CoV-2 by blocking host surface receptors, resulting in a reduction of virus load into cell.^[@ref11]^ Other supporting data, mouse β-defensin-4 (mBD4) also shows strong antiviral activity against SARS-CoV *in vitro* and *in vivo*.^[@ref12]^

In spite of large numbers of AMPs presence in human saliva, COVID-19 infection spreads through infected human droplets, saliva, or sputum. Many clinical reports often identify the virus from saliva samples of the infected.^[@ref13]^ This outcome is unlike that for HD5. Still, there is no explanation, but we can propose that either saliva has limited antiviral activity^[@ref13]^ against SARS-CoV-2, or the acidic pH factor at stomach may play a key role to kill the virus, when the virus reaches the intestine through the stomach. In addition, different AMPs have different antiviral effects due to their diverse amino acid sequences and structures.^[@ref13]^ Therefore, HD5 cannot be ruled out as antiviral agent against SARS-CoV-2.

Milk is an essential micronutrient for humans that boosts the host's innate and adaptive immunity against infection. Interestingly, lactoferrin (Lf) is one class of AMP and iron-binding glycoprotein that is derived from food sources, mainly milk, and plays as first-line host defense against multiple pathogens, including virus.^[@ref14]^ The antiviral activity of Lf against SARS-CoV infection was demonstrated first by Lang et al., where Lf interfered with virus adsorption on the host surface receptors by blocking.^[@ref15]^ During infection, Lf expression is elevated (approximately 150 fold) in SARS patients compared with the control experiment.^[@ref15]^ Therefore, Lf is likely to be considered as a promising antiviral therapy against SARS-CoV-2 infection.^[@ref16]^ One clinical report says that children are at a lesser risk from COVID-19. This outcome seems to be the result of the presence of a high level of Lf in plasma by breast-feeding or sufficient milk consumption, but it is not yet established. However, dietary factor, particular, endogenous Lf deficiency, may affect the host immune response in COVID-19 patients. Therefore, a sufficient consumption of milk might produce a high abundance of Lf in the human body that may help to prevent this current pandemic.

Overall, AMP would be a better choice as an antiviral agent because it occurs naturally, it is safe and nontoxic, and it is an innate host defense peptide. Several AMPs to date have been called for clinical trials.^[@ref8]^ Preliminarily, more AMPs, those having potent antiviral activity, can be selected as antiviral drugs for the treatment of COVID-19. The antiviral potency and activity of AMPs could be enhanced by conjugation with conventional antiviral drugs, such as Lf conjugated with an antiviral drug.^[@ref8],[@ref14]^ Furthermore, many natural AMPs have a metal binding motif, ATCUN (N-terminus Cu^II^ and Ni^II^ binding motif with H~2~N-X-X-H sequence; X = any amino acid and H = histidine),^[@ref7]^ that shows antiviral activity against an enveloped virus by oxidative modification.^[@ref17]^ So, antiviral peptide would be a promising therapeutic route for prevention of COVID-19.
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